![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
October 17, 2024
August 22, 2024
This phase 3 study is comparing BRAF-targeted therapy with dabrafenib-trametinib to TKI therapy with cabozantinib in patients with disease progression following standard treatments
August 14, 2024
A Scientific Member of ECOG-ACRIN since 2012
August 14, 2024
Summaries of recently published ECOG-ACRIN research results
August 14, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
July 3, 2024
Summaries of recently published ECOG-ACRIN research results
June 11, 2024
This phase 2 study is testing two variations of the triplet combination of azacitidine, venetoclax, and gilteritinib compared to standard therapy
June 11, 2024
Dustin A. “Dusty” Deming, MD, is the young investigator of the year for the ECOG-ACRIN Cancer Research Group
June 11, 2024
The group is recognizing Dr. Wakelee for her sustained commitment to developing women’s careers in cancer medicine and advancing women investigators in ECOG-ACRIN
June 11, 2024
Summaries of five ECOG-ACRIN trials presented at the 2024 American Society of Clinical Oncology Annual Meeting
June 11, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
June 13, 2024
This randomized phase 3 trial is comparing treatment with chemotherapy alone or with immunotherapy